Skip to main content

IGHV Somatic Hypermutation

IgVH Somatic Hypermutation
IGHV Somatic Hypermutation
Test Number 113753
Test number copied
CPT

81263
Synonyms
  • IGHV Gene Mutation
  • Immunoglobulin Heavy Chain Variable Region Somatic Hypermutation Analysis
  • IgVH Gene Mutation
  • Immunoglobulin Heavy Chain Variable Region Somatic Hypermutation Analysis
  • IGHV Gene Mutation
  • Immunoglobulin Heavy Chain Variable Region Somatic Hypermutation Analysis
  • Share
  • Print
  • Updated on 02/21/2025

Test Details

Methodology

The immunoglobulin heavy-chain gene variable region (IGHV) somatic hypermutation analysis is performed using extracted patient RNA as starting material. Subsequent amplification of the IgH gene is performed by polymerase chain reaction (PCR). The PCR products are isolated and sequenced. The nucleotide sequence is compared to a consensus germline sequence data base for that VH gene family. The results are reported as percentage of homology between the patient's VH sequence in comparison with the germline VH sequence using the Basic Local Alignment Search Tool (BLAST) for the Immunoglobulin data base at http://www.ncbi.nlm.nih.gov/igblast.

The immunoglobulin heavy-chain gene variable region (IgVH) somatic hypermutation analysis is performed using extracted patient RNA as starting material. Subsequent amplification of the IgH gene is performed by polymerase chain reaction (PCR). The PCR products are isolated and sequenced. The nucleotide sequence is compared to a consensus germline sequence data base for that VH gene family. The results are reported as percentage of homology between the patient's VH sequence in comparison with the germline VH sequence using the Basic Local Alignment Search Tool (BLAST) for the Immunoglobulin data base at http://www.ncbi.nlm.nih.gov/igblast.

The immunoglobulin heavy-chain gene variable region (IGHV) somatic hypermutation analysis is performed using extracted patient RNA as starting material. Subsequent amplification of the IgH gene is performed by polymerase chain reaction (PCR). The PCR products are isolated and sequenced. The nucleotide sequence is compared to a consensus germline sequence data base for that VH gene family. The results are reported as percentage of homology between the patient's VH sequence in comparison with the germline VH sequence using the Basic Local Alignment Search Tool (BLAST) for the Immunoglobulin data base at http://www.ncbi.nlm.nih.gov/igblast.

Result Turnaround Time

6 - 8 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Use

This test determines the mutation status of IGHV gene in B lymphocytes, including those of CLL (chronic lymphocytic leukemia). The IGHV gene mutation status is one of the discriminators of clinical outcome in patients with CLL. The mutational status of the immunoglobulin genes expressed by CLL cells can be used to segregate patients into two subsets that have significantly different tendencies for disease progression. Patients with leukemic cells that express unmutated immunoglobulin heavy-chain variable region genes have a greater tendency for disease progression than those who have leukemic cells that express IGHV genes with less than 98% nucleic acid homology with their germ-line counterparts.

Determines the mutation status of IgVH gene in B lymphocytes, including those of CLL (chronic lymphocytic leukemia). The IgVH gene mutation status is one of the discriminators of clinical outcome in patients with CLL. The mutational status of the immunoglobulin genes expressed by CLL cells can be used to segregate patients into two subsets that have significantly different tendencies for disease progression. Patients with leukemic cells that express unmutated immunoglobulin heavy-chain variable region genes have a greater tendency for disease progression than those who have leukemic cells that express IgVH genes with less than 98% nucleic acid homology with their germ-line counterparts.

This test determines the mutation status of IGHV gene in B lymphocytes, including those of CLL (chronic lymphocytic leukemia). The IGHV gene mutation status is one of the discriminators of clinical outcome in patients with CLL. The mutational status of the immunoglobulin genes expressed by CLL cells can be used to segregate patients into two subsets that have significantly different tendencies for disease progression. Patients with leukemic cells that express unmutated immunoglobulin heavy-chain variable region genes have a greater tendency for disease progression than those who have leukemic cells that express IGHV genes with less than 98% nucleic acid homology with their germ-line counterparts.

Limitations

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

Specimen Requirements

Specimen

Peripheral blood or bone marrow

Volume

1 mL

Minimum Volume

0.5 mL

Container

Lavender-top (EDTA) tube, green-top (heparin) tube or yellow-top (ACD) tube

Lavender-top (EDTA) tube, green-top (heparin) tube, or yellow-top (ACD) tube

Lavender-top (EDTA) tube, green-top (heparin) tube or yellow-top (ACD) tube

Storage Instructions

Maintain specimen at room temperature; stable for three to five days.

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
113753 IGHV Somatic Hypermutation 111001 Interpretation: 62365-2
113753 IGHV Somatic Hypermutation 481541 PDF 80563-0
Order Code113753
Order Code NameIGHV Somatic Hypermutation
Order Loinc
Result Code111001
Result Code NameInterpretation:
UofM
Result LOINC62365-2
Order Code113753
Order Code NameIGHV Somatic Hypermutation
Order Loinc
Result Code481541
Result Code NamePDF
UofM
Result LOINC80563-0